AAX Biotech Announces Collaboration with Daiichi Sankyo to Evaluate Opti-mAb® Technology in Next-Generation Antibody Therapeutics
Stockholm, Sweden, Oct 22, 2025 — Swedish biotech company AAX Biotech AB announces a collaboration with Daiichi Sankyo, one of the global leaders in antibody-drug conjugates (ADCs). The collaboration marks a significant milestone for AAX Biotech, underscoring the potential of its proprietary Opti-mAb® technology for innovative antibody therapeutics.
AAX Biotech pioneers innovative technologies that advance the development of next-generation antibody therapeutics. Its two platforms, Seqitope® and Opti-mAb®, address key challenges in antibody engineering and therapeutic design, supporting the creation of more effective and developable medicines.
Daiichi Sankyo through its Daiichi Sankyo Research Institute in Munich will evaluate the capabilities of Opti-mAb® and explore opportunities for broader collaboration aimed at addressing critical unmet medical needs. AAX Biotech’s unique Opti-mAb® platform stabilizes the inherently unstable single-chain variable fragment (scFv) antibodies.
“For AAX Biotech, collaborating with a company with the scale and reputation of Daiichi Sankyo represents a tremendous validation of our innovative approach,” says Maria Lisa Knudsen, CEO of AAX Biotech. “This provides us with the opportunity to showcase the power of Opti-mAb® in collaboration with a truly global leader in pharmaceutical innovation. We are excited to work closely with the world-class scientific teams at Daiichi Sankyo.”
This collaboration highlights AAX Biotech commitment to exploring cutting-edge science to advance precision medicine and improve patient outcomes worldwide.
For more information, please contact:
Maria Lisa Knudsen, CEO
+46 72 939 5018
maria.knudsen@aaxbiotech.com
About AAX Biotech AB
AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope® and Opti-mAb®, that enable high-throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by experts from Karolinska Institutet in Stockholm, Sweden. Visit aaxbiotech.com to learn more and follow AAX Biotech on LinkedIn.